What Is Bioprocessing and Why Does It Matter?

Bioprocessing is the use of living cells, or the molecular machinery extracted from them, to manufacture products at industrial scale. It is how most of the world’s insulin, monoclonal antibody therapies, and vaccines get made, and increasingly how companies produce specialty foods, biofuels, and biodegradable plastics. The field traces back to some of the oldest human technologies, from brewing beer to fermenting vinegar, but modern bioprocessing looks nothing like a brewery. It involves engineered cell lines grown in carefully controlled bioreactors, sophisticated purification trains, and digital monitoring systems that track dozens of variables in real time. Understanding why it matters starts with grasping just how many products now depend on it and how quickly the list is growing.

From Beer to Biologics

The roots of bioprocessing are genuinely ancient. Fermentation of beer, wine, and bread relied on yeast long before anyone knew yeast was alive. Louis Pasteur’s nineteenth-century demonstration that living microorganisms drove fermentation launched the industrial exploitation of biology in earnest, leading to manufactured citric acid, acetone, butanol, and eventually penicillin during the Second World War.¹ Each generation of bioprocessing built on the last: antibiotics gave way to steroid biotransformations, then to recombinant proteins made possible by molecular biology in the 1970s and 1980s. Today the field encompasses everything from growing mammalian cells that secrete therapeutic antibodies to engineering bacteria that convert plant waste into ethanol.

How a Bioprocess Is Organized

Any bioprocess splits into two broad phases. The upstream phase is where the biology happens: cells are selected, grown, and coaxed into producing a target molecule. The downstream phase is where the product gets separated from everything else, purified, concentrated, and prepared for use. Both halves present distinct engineering challenges, and improvements in one often create bottlenecks in the other.

On the upstream side, choosing the right cell line and the right growth conditions is critical. For monoclonal antibodies, the workhorse is the Chinese hamster ovary (CHO) cell, which can be engineered to secrete large quantities of a desired protein. Selecting top-performing clones from a pool of candidates is not trivial; researchers use clustering algorithms and multi-attribute screening to identify cells that combine high productivity with consistent product quality.² Media composition, feeding schedules, temperature shifts, and dissolved oxygen levels all need optimization, and a change in any one of them can alter how the protein folds or how sugars attach to it.

Downstream processing then takes the broth from the bioreactor and removes host-cell proteins, DNA, aggregates, and other impurities to produce a product pure enough for its intended use. In pharmaceutical manufacturing, purity requirements are extreme. Chromatography columns, filtration membranes, and viral inactivation steps are sequenced into a purification train that can itself cost as much as the bioreactor. Downstream processing remains one of the major cost drivers in biopharmaceutical production.

Pharmaceutical Manufacturing and Why CHO Cells Dominate

The pharmaceutical industry is the single largest user of advanced bioprocessing. Monoclonal antibodies alone represent a market worth hundreds of billions of dollars, and nearly all of them are produced in CHO cells. The reason is partly historical, partly practical: CHO cells fold human-like proteins well, they can be adapted to grow in suspension without animal serum, and decades of regulatory filings have built a massive base of safety data around them. An industry-academic consortium has even created shared reference cell lines to standardize research and reduce the proprietary fragmentation of the field.³

Productivity has climbed steeply. Optimized perfusion culture strategies can push antibody titers above 16 grams per liter in bioreactors scaled to 200 liters, numbers that would have seemed implausible two decades ago.⁴ Yet not every clone cooperates. Individual cell lines vary enormously in how much protein they secrete, from single-digit picograms per cell per day to over 70, and understanding what makes a stable high producer remains an active area of study.⁵

Vaccine manufacturing presents its own bioprocessing challenges. During the COVID-19 pandemic, the difference between production platforms became starkly visible. mRNA vaccines can be produced in a cell-free process that is roughly 200 to 300 times more productive per liter per year than adenoviral vector vaccines, which depend on growing cells and harvesting virus particles. Self-amplifying RNA pushes that advantage even further, with predicted productivity about 20 times greater than conventional mRNA.⁶ These differences in bioprocessing efficiency directly affected how quickly billions of doses could be manufactured.

Batch Versus Continuous Production

Most biopharmaceuticals are still made in fed-batch mode: a bioreactor is loaded with cells and media, run for about two weeks, harvested, cleaned, and started again. It is a proven, well-understood approach. But continuous processing, where fresh media flows in and product is harvested nonstop over weeks or months, is gaining ground. In 50-day perfusion runs, researchers have maintained high viable cell densities and harvested more than a gram per liter per day of antibodies.⁷

Continuous processing can deliver substantially higher bioreactor productivity, with perfusion systems reaching over 2 grams per liter per day compared to under half a gram per liter per day in fed-batch.⁸ The trade-off is cost structure. Media costs run higher in perfusion because fresh nutrient solution is continuously supplied, potentially accounting for a larger share of total costs. However, continuous processes can use smaller bioreactors, smaller chromatography columns, and fewer hold tanks, which shrinks the facility footprint.⁹ The choice between batch and continuous depends on the specific product, the volume needed, and how a company weighs capital costs against operating costs.

The Scale-Up Problem

A process that works in a small lab flask often fails when transferred to a manufacturing-scale bioreactor holding thousands of liters. The core difficulty is physical: as a vessel gets larger, mixing becomes uneven, oxygen delivery changes, and cells in different parts of the reactor experience different shear forces. For mammalian cells, which are far more fragile than bacteria, these hydrodynamic stresses can reduce productivity or kill cells outright. Researchers use computational fluid dynamics to map shear environments inside bioreactors and have found that average shear stress correlates with drops in product titer, giving engineers a measurable target to control during scale-up.¹⁰

Novel bioreactor designs are part of the answer. Coaxial bioreactors, which use a different arrangement of impellers, have shown promise for filamentous fungi and other shear-sensitive organisms. These systems can deliver good oxygen transfer while keeping the shear environment more uniform, and initial scale-up studies suggest they maintain their performance characteristics at larger volumes.¹¹ Still, scale-up remains one of the field’s most persistent headaches, particularly for newer applications where the biology has not been as thoroughly characterized as CHO cell culture.

Food, Fermentation, and Cultivated Meat

Bioprocessing is increasingly reaching into the food system. Precision fermentation uses engineered microorganisms, typically yeast, bacteria, or fungi, to produce specific food proteins that traditionally came only from animals. Milk proteins like whey and casein are among the highest-profile targets, with recent advances in host engineering and secretion capacity moving these products from proof-of-concept toward commercial production.¹² The appeal is straightforward: produce a molecularly identical protein without the cow, the land use, or the methane emissions.¹³

Cultivated meat takes a different and more difficult path: growing actual animal muscle and fat cells in bioreactors. The bioprocessing challenges are formidable. Cells are typically grown on microcarriers, tiny beads that provide a surface for attachment, and optimizing when and how to add fresh microcarriers without disrupting growth is an active research problem. Recent work found that adding microcarriers when cell density is still moderate, around 15,000 cells per square centimeter, and using high expansion ratios can simplify the process to as few as one addition step, reducing contamination risk and labor.¹⁴ Despite such progress, economic analyses consistently find that cultivated meat is not yet competitive with conventional meat under current technology. The gap will not close without breakthroughs in serum-free differentiation, new bioreactor designs, and more realistic facility planning.¹⁵

Biofuels and Green Chemicals

Converting plant biomass into fuels and chemicals through fermentation is one of the oldest ambitions of industrial bioprocessing, and also one of the most stubborn. Lignocellulosic biomass, the structural material in crop residues and wood, is abundant and cheap, but breaking it down releases a mix of sugars and toxic byproducts that most conventional yeast strains handle poorly. Researchers are now developing non-conventional yeasts using CRISPR-based genome editing, adaptive evolution, and transporter engineering to build organisms that can ferment real lignocellulosic hydrolysates rather than just synthetic sugar solutions, producing ethanol and valuable co-products like riboflavin under harsh industrial conditions.¹⁶

Biodegradable plastics offer another angle. Polyhydroxyalkanoates, or PHAs, are polyesters that bacteria accumulate naturally, and bioprocessing can produce them from food waste. Life cycle analysis of one modular system showed a net negative carbon footprint: roughly minus 2.7 kilograms of CO₂ equivalent per kilogram of PHA produced, because the diversion of food waste from landfill offsets the emissions from fermentation and extraction.¹⁷ That kind of result is exactly the environmental promise bioprocessing enthusiasts point to, though the economics remain tighter than for petroleum-based plastics.

Environmental Footprint and Equipment Choices

Bioprocessing often starts from renewable feedstocks rather than fossil ones, which gives it a theoretical environmental advantage. But that advantage is not automatic. Life cycle assessments of early-stage bioprocesses reveal that substrate provision, energy for bioreactor aeration, and purification solvents can all be major contributors to environmental impact.¹⁸ The push to perform these assessments early in development, before a process is locked in, is growing, because retrofitting a scaled process is far more expensive than designing it sustainably from the start.¹⁹

Equipment choices play a role too. Traditional stainless-steel bioreactors require steam sterilization between batches, consuming large amounts of electricity and water. Single-use bioreactors, essentially pre-sterilized plastic bags supported by rigid frames, eliminate the cleaning step. At laboratory scale, a life cycle comparison found single-use systems emitted about 8.7 kilograms of CO₂ equivalent per gram of protein produced, compared to 14.9 kilograms for stainless steel, with electricity being the dominant cost in both cases.²⁰ Single-use systems generate plastic waste, of course, so the environmental calculus is not simple, but their lower energy demand at small scales is clear.

Quality, Regulation, and Digital Monitoring

Because many bioprocessed products end up in people’s bodies, the regulatory bar is high. Pharmaceutical bioprocessing operates under a framework called Quality by Design, which requires manufacturers to identify which product attributes are critical, figure out which process parameters affect those attributes, and build a control strategy around the whole system.²¹ Contamination control adds another layer of complexity. In cell culture media manufacturing, for example, risk management tools borrowed from the food industry are used to identify and mitigate contamination hazards at every step, from raw-material intake through sterile filling.²²

Digital tools are transforming how manufacturers monitor and control these processes. Process analytical technology, or PAT, encompasses the inline sensors, spectroscopic methods, and software models that let operators track product quality in real time instead of relying on end-of-batch testing. The most ambitious extension is the digital twin, a computational model of the entire bioprocess that can predict how a change in one variable will ripple through the system. These twins are becoming especially relevant for continuous manufacturing, where real-time control is essential because there are no pauses to test and adjust between batches.²³

The Economics of Building a Bioprocessing Facility

Bioprocessing facilities are expensive. A traditional large-scale stainless-steel plant for antibody manufacturing can cost hundreds of millions of dollars and take years to build. That upfront capital burden is part of why biologic drugs tend to be costly. Integrated continuous biomanufacturing platforms offer a potential escape: process modeling has shown that they can cut average costs by roughly 55% compared to conventional batch processing over a ten-year product portfolio, with additional savings when demand is higher than expected.²⁴

Flexible, modular facility designs are another strategy. Portable-on-demand units, essentially self-contained cleanrooms in shipping-container-sized pods, can be combined and reconfigured as product needs change. Scenario modeling has shown that such designs can buffer manufacturers against swings in market demand, which otherwise have dramatic effects on per-unit cost and plant utilization.²⁵ Getting the economics right matters beyond the balance sheet: manufacturing cost ultimately feeds into drug pricing, and lower production costs can widen patient access.

New Host Organisms Beyond CHO and E. coli

While CHO cells and Escherichia coli remain the default platforms for pharmaceutical bioprocessing, the palette of useful organisms is expanding. Pseudomonas putida, a soil bacterium prized for its chemical tolerance, is being developed as a chassis for producing specialty chemicals and even degrading environmental pollutants.²⁶ Corynebacterium glutamicum, already used at enormous scale for amino acid production, is being retrofitted with synthetic biology toolkits for broader biomanufacturing tasks.²⁷ And salt-tolerant bacteria in the genus Halomonas are attracting attention because they grow in high-salinity conditions that discourage contamination, potentially allowing non-sterile fermentation, a huge cost saver.²⁸ Each new host organism brings trade-offs in productivity, genetic tractability, and regulatory acceptance, but the direction is clear: the bioprocessing toolkit is getting wider.

Cell-Free Systems

An emerging alternative to growing whole cells is to skip the cell entirely. Cell-free protein synthesis uses the extracted molecular machinery, ribosomes, enzymes, energy cofactors, but without a living cell around them. The advantage is speed and flexibility: there are no growth cycles to wait through, no worries about keeping cells alive, and the reaction environment can be tuned freely by adding or removing components.²⁹ Cell-free systems are particularly useful for producing proteins that are toxic to living cells or that fold poorly inside them.³⁰ For now, cell-free production is mainly used for research, diagnostics, and small-batch manufacturing. Scaling it to compete with microbial fermentation for bulk chemicals is a different challenge, but the platform’s versatility makes it a space to watch.

A Workforce That Has Not Caught Up

All of these technological advances are bumping against a practical constraint: people. Bioprocessing is a multidisciplinary field that draws on cell biology, chemical engineering, data science, and regulatory affairs. Surveys of employers in regenerative medicine biomanufacturing found that 20 to 40 percent report a lack of needed skill sets in their workforce and an inability to hire for them.³¹ Broader analyses project that workforce shortages could threaten operational capacity across the biomanufacturing sector by 2035, with recommended responses including stronger industry-academia partnerships, expanded non-degree certification pathways, and mentorship programs designed to bring in workers from nontraditional backgrounds.³² Automation and digital twins can reduce the number of hands needed on the floor, but someone still has to design, validate, and troubleshoot those systems. The bottleneck is human capital as much as hardware.